Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria

• ClinicalTrials.gov Identifier: NCT01754701
• Recruitment Status: Completed
• First Posted: December 21, 2012
• Last Update Posted: November 30, 2015
• Sponsor: University of Minnesota
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Information provided by (Responsible Party): University of Minnesota

Study Description

Brief Summary:

The purpose of this study is to determine whether iron therapy given to iron-deficient Ugandan children with moderate-to-severe anemia and clinical malaria is better absorbed and incorporated into red blood cells if it is given concurrently with antimalarial treatment on Day 0 (immediate group) or 4 weeks after antimalarial treatment on Day 28 (delayed group). Use of iron stable isotopes 57Fe and 58Fe will permit measurement of red blood cell iron incorporation on Day 0 and Day 28 in all children. The investigators hypothesize that red cell iron incorporation at the time of initial supplement administration will be greater in children receiving delayed vs. immediate iron (Aim 1), and children in the delayed group will also have greater hematological recovery on Day 56 than children in the immediate group (Aim 2).

Condition or disease	Intervention/treatment	Phase
Iron Deficiency; Malaria; Nutrition; Global Health	Dietary Supplement: Immediate iron; Dietary Supplement: Delayed iron	Not Applicable

Detailed Description:

Approximately 1 million children < 5 y living in sub-Saharan Africa die from severe anemia annually. This severe anemia frequently results from coexisting iron deficiency and malaria infection, but the standard of care, concurrent iron therapy and antimalarial treatment, has proven ineffective at curing the profound anemia and has promoted proliferation of the parasite in some studies. The pro-inflammatory immune response mounted against malaria down-regulates iron absorption in the gut, making provision of oral iron supplements during malarial infection of questionable utility. The present study proposes to use iron stable isotopes and a randomized design to test whether starting 4 weeks of iron therapy immediately after antimalarial treatment or 4 weeks later is associated with greater iron incorporation into red blood cells at the time of initial administration of iron therapy and improved long-term hematological recovery. One hundred severely anemic (hemoglobin 5-9.9 g/dL) Ugandan children 6-59 mos with clinical signs of malaria who present to the Pediatric Acute Care Ward of Mulago Hospital in Kampala, Uganda, will be randomized to start iron immediately after antimalarial treatment on Day 0 (immediate group) or 4 weeks later on Day 28 (delayed group). Children will be assessed at the hospital on Day 0, Day 28 and Day 56 and will receive bi-weekly home visits for the 56-day study duration. The specific aims and corresponding hypotheses of the proposed study are:

Aim 1: Identify the sequencing of antimalarial treatment and iron therapy that results in the greatest red cell iron incorporation at the time of initial iron supplement administration. The working hypothesis is that red cell iron incorporation will be greater at the time of initial supplement administration in children starting iron 4 weeks after antimalarial treatment (delayed group) compared to children starting iron concurrently with antimalarial treatment (immediate group), due to more complete parasite clearance and resolution of inflammation, permitting better iron uptake, distribution, and utilization.

Aim 2: Determine whether long-term hematological recovery is impacted by immediate vs. delayed iron. The working hypothesis is that delayed iron treatment will be associated with greater hemoglobin and improved iron status at Day 56 compared to immediate treatment due to more complete parasite clearance and consequent improved iron absorption and use in the delayed group.

The results of this study will establish a physiologically-based framework for the optimal timing of antimalarial treatment and iron therapy upon which future interventions aimed at improving iron status in malaria-endemic regions can be built, thus helping to reduce the morbidity and mortality and ensure the full neurobehavioral development of the millions of severely anemic children suffering from iron-deficiency and malaria.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 100 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria
• Study Start Date: June 2013
• Actual Primary Completion Date: May 2015
• Actual Study Completion Date: May 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Immediate iron; Children who start 4 weeks of iron therapy on Day 0	Dietary Supplement: Immediate iron; Children who start 4 weeks of iron therapy on Day 0; Other Name: Ferrous sulfate syrup
Experimental: Delayed iron; Children who start 4 weeks of iron therapy on Day 28	Dietary Supplement: Delayed iron; Children who start 4 weeks of iron therapy on Day 28

Outcome Measures

Primary Outcome Measures :

1. Percent red blood cell iron incorporation on Day 0 in children in the immediate group vs. percent red blood cell iron incorporation on Day 28 in children in the delayed group [ Time Frame: 56 days ]
   All children will receive iron stable isotope 57Fe on Day 0 and iron stable isotope 58Fe on Day 28. Children in the immediate group will begin 27 days of daily iron syrup at home on Day 1. Children in the delayed group will begin 27 days of daily iron syrup at home on Day 29. All children will be assessed at the hospital at Day 28 and Day 56.

Secondary Outcome Measures :

1. Hematological recovery in the immediate vs. delayed groups on Day 56 [ Time Frame: 56 days ]
   All children will receive iron stable isotope 57Fe on Day 0 and iron stable isotope 58Fe on Day 28. Children in the immediate group will begin 27 days of daily iron syrup at home on Day 1. Children in the delayed group will begin 27 days of daily iron syrup at home on Day 29. All children will be assessed at the hospital at Day 28 and Day 56.

Eligibility Criteria

• Ages Eligible for Study: 6 Months to 59 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. 6 - 59 months of age
2. Hemoglobin 5.0 - 9.9 g/dL according to HemoCue
3. Temperature > 37.5°C or history of fever in past 24 hours
4. P. falciparum on blood smear at Acute Care Unit
5. Residence<50 km of study hospital

Exclusion Criteria:

1. Impaired consciousness on physical exam or history of coma with present illness
2. Seizure activity prior to or during admission
3. Known sickle cell disease 4) Acute malnutrition

Contacts and Locations

Locations

Uganda

Mulago Hospital

Kampala, Uganda

Sponsors and Collaborators

University of Minnesota

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators

• Principal Investigator: Sarah Cusick, Ph.D.; University of Minnesota

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cusick SE, Opoka RO, Abrams SA, John CC, Georgieff MK, Mupere E. Delaying Iron Therapy until 28 Days after Antimalarial Treatment Is Associated with Greater Iron Incorporation and Equivalent Hematologic Recovery after 56 Days in Children: A Randomized Controlled Trial. J Nutr. 2016 Sep;146(9):1769-74. doi: 10.3945/jn.116.233239. Epub 2016 Jun 29. Erratum in: J Nutr. 2019 Jul 1;149(7):1294.

• Responsible Party: University of Minnesota
• ClinicalTrials.gov Identifier: NCT01754701
• Other Study ID Numbers: 1203M11234; 1R03HD074262 ( U.S. NIH Grant/Contract )
• First Posted: December 21, 2012
• Last Update Posted: November 30, 2015
• Last Verified: November 2015

Additional relevant MeSH terms:

Malaria; Protozoan Infections; Parasitic Diseases; Iron; Trace Elements; Micronutrients; Nutrients; Growth Substances; Physiological Effects of Drugs